References
- Åberg F, Gissler M, Karlsen TH, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 2015;61(2):668–677.
- Allen AM, Kim WR, Therneau TM, et al. Chronic kidney disease and associated mortality after liver transplantation–a time-dependent analysis using measured glomerular filtration rate. J Hepatol. 2014;61(2):286–292.
- Herlenius G, Fistouris J, Olausson M, et al. Early renal function post-liver transplantation is predictive of progressive chronic kidney disease. Scand J Gastroenterol. 2008;43(3):344–349.
- Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931–940.
- Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
- Glover TE, Watson CJ, Gibbs P, et al. Conversion from calcineurin to mammalian target of rapamycin inhibitors in liver transplantation: a meta-analysis of randomized controlled trials. Transplantation. 2016;100(3):621–629.
- LaMattina JC, Mezrich JD, Fernandez LA, et al. Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant. 2013;27(2):193–202.
- Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transpl. 2012;12(3):694–705.
- Asrani SK, Leise MD, West CP, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology. 2010;52(4):1360–1370.
- De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15(10):1262–1269.
- Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant. 2012;12(7):1855–1865.
- Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transpl. 2009;9(2):327–336.
- Zitta S, Schaffellner S, Gutschi J, et al. The effect of mammalian target of rapamycin versus calcineurin inhibitor-based immunosuppression on measured versus estimated glomerular filtration rate after orthotopic liver transplantation. Transplantation. 2015;99(6):1250–1256.
- Jeng LB, Lee SG, Soin AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2018;18(6):1435–1446.
- Wadei HM, Zaky ZS, Keaveny AP, et al. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients. Transplantation. 2012;93(10):1006–1012.
- Li LC, Hsu CN, Lin CC, et al. Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients. BMC Gastroenterol. 2017;17(1):58.
- Sterneck M, Kaiser GM, Heyne N, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant. 2016;30(6):741–748.
- Bendz H. Metoder för njurfunktionsbestämning - vad har vi att erbjuda idag? Lakartidningen. 2002;99:3851–3856.
- Pillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant. 2005;5(5):1120–1129.
- Tsai CW, Ting IW, Yeh HC, et al. Longitudinal change in estimated GFR among CKD patients: a 10-year follow-up study of an integrated kidney disease care program in Taiwan. PloS One. 2017;12(4):e0173843.
- Wagner D, Kniepeiss D, Stiegler P, et al. The assessment of GFR after orthotopic liver transplantation using cystatin C and creatinine-based equations. Transpl Int. 2012;25(5):527–536.